Pesquisar
Aligos Therapeutics Inc
ALGSAdicionar à lista de desejos
4.230USD
-0.090-2.08%
Fechamento 07-31 16:00（ET）Cotações atrasadas em 15 min
26.18MValor de mercado
PerdaP/L TTM
Mais detalhes de Aligos Therapeutics Inc Empresa
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
Informações de Aligos Therapeutics Inc
Código da empresaALGS
Nome da EmpresaAligos Therapeutics Inc
Data de listagemOct 16, 2020
CEOBlatt (Lawrence M)
Número de funcionários70
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 16
EndereçoOne Corporate Dr., 2Nd Floor
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone18004666059
Sitehttps://www.aligos.com/
Código da empresaALGS
Data de listagemOct 16, 2020
CEOBlatt (Lawrence M)
Executivos da empresa Aligos Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Dr. Bridget A. Martell, M.D.
Dr. Bridget A. Martell, M.D.
Independent Director
Independent Director
--
--
Mr. Jordyn Tarazi
Mr. Jordyn Tarazi
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Dr. Heather Preston, M.D.
Dr. Heather Preston, M.D.
Independent Director
Independent Director
--
--
Ms. Margarita Chavez, J.D.
Ms. Margarita Chavez, J.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Lawrence M. Blatt, Ph.D.
Dr. Lawrence M. Blatt, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
88.42K
--
Dr. Julian A. Symons
Dr. Julian A. Symons
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
35.11K
+55.11%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Chief Financial Officer, Chief Operating Officer, Executive Vice President
Chief Financial Officer, Chief Operating Officer, Executive Vice President
5.22K
+30.85%
Mr. James P. (Jim) Scopa, J.D.
Mr. James P. (Jim) Scopa, J.D.
Independent Director
Independent Director
--
--
Dr. K. Peter Hirth, Ph.D.
Dr. K. Peter Hirth, Ph.D.
Independent Director
Independent Director
--
--
Ms. Carole L. Nuechterlein, J.D.
Ms. Carole L. Nuechterlein, J.D.
Independent Director
Independent Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Aligos Therapeutics Inc?
Os cinco principais acionistas de Aligos Therapeutics Inc são: Dr. Lawrence M. Blatt, Ph.D.
Quantas instituições possuem ações da Aligos Therapeutics Inc (ALGS)?
Em 2026Q1, 108 instituições possuíam ações da Aligos Therapeutics Inc, com valor de mercado aproximado de 2.82M, representando 52.29% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1521590.00.